Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-DOTA-Trastuzumab PET Imaging in HER2+ Breast Cancer
NCT02827877Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Feb 2018
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 64Cu-DOTA-trastuzumab in breast cancer, sponsored by City of Hope. Started Feb 2018; status: active, not recruiting.
02
Drugs
64Cu-DOTA-trastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02827877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02827877.